


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<div style="text-align: center;">  <p>TRANSMITTAL FORM</p> <p><i>(to be used for all correspondence after filing)</i></p> <p>Total number of Pages in this submission 14</p> </div>	Application Number	09/922,405
	Filing Date	August 3, 2001
	First Named Inventor	Charles A. Nicolette
	Group Art Unit	1642
	Examiner Name	Unassigned
	Attorney Docket No.	GZ 2103.00

U.S. Patent & Trademark Office
 Box Sequence
 P.O. Box 2327
 Arlington, VA 22202

ENCLOSURES (check all that apply)		
<input type="checkbox"/> FEE TRANSMITTAL FORM <input type="checkbox"/> FEE ATTACHED <input type="checkbox"/> AMENDMENT/RESPONSE <input type="checkbox"/> AFTER FINAL <input type="checkbox"/> AFFIDAVITS' DECLARATION(S) <input type="checkbox"/> EXTENSION OF TIME <input type="checkbox"/> EXPRESS ABANDONMENT REQUEST <input type="checkbox"/> SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT W/1449 <input type="checkbox"/> CERTIFIED COPY OF PRIORITY DOCUMENT(S) <input type="checkbox"/> RESPONSE TO MISSING PARTS/ INCOMPLETE APPLICATION <input type="checkbox"/> RESPONSE TO MISSING PARTS UNDER 37 CFR 1.52 OR 1.53 COPY OF PTO-1533 <input type="checkbox"/> ISSUE FEE TRANSMITTAL	<input type="checkbox"/> ASSIGNMENT PAPERS (FOR AN APPLICATION) <input type="checkbox"/> DRAWING(S) <input type="checkbox"/> LICENSING-RELATED PAPERS <input type="checkbox"/> PETITION ROUTING SLIP (PTO/SB/60) AND ACCOMPANYING PETITION) <input type="checkbox"/> TO CONVERT A PROVISIONAL APPLICATION <input type="checkbox"/> POWER OF ATTORNEY, REVOCATION CHANGE OF CORRESPONDENCE ADDRESS <input type="checkbox"/> TERMINAL DISCLAIMER <input type="checkbox"/> SMALL ENTITY STATEMENT <input type="checkbox"/> REQUEST FOR REFUND	<input type="checkbox"/> AFTER ALLOWANCE COMMUNICATION TO GROUP <input type="checkbox"/> APPEAL COMMUNICATION TO BOARD OF APPEALS AND INTERFERENCES <input type="checkbox"/> APPEAL COMMUNICATION TO GROUP (APPEAL NOTICE, BRIEF, REPLY BRIEF) <input type="checkbox"/> PROPRIETARY INFORMATION <input type="checkbox"/> STATUS LETTER <input checked="" type="checkbox"/> ADDITIONAL ENCLOSURE(S) (PLEASE IDENTIFY BELOW): RESPONSE TO NOTICE TO COMPLY, PAPER SEQUENCE LISTING (10 PGS), COPY OF NOTICE TO COMPLY DATED 3/18/2002, COMPUTER READABLE DISKETTE CONTAINING SEQUENCE LISTING AND RETURN POSTCARD

MCCUTCHEN, DOYLE, BROWN & ENERSEN LLP
 THREE EMBARCADERO CENTER, SUITE 1800
 SAN FRANCISCO, CA 94111
 TELEPHONE: (650) 849-4950
 FACSIMILE: (650) 849-4800

DATE: APRIL 2, 2002

BY: _____

Antoinette F. Konski
 ANTOINETTE F. KONSKI (REG. NO. 34,202)

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent & Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on this date: April 2, 2002

By: _____

Peggy Nichols

Name of person signing: Peggy Nichols



Docket No. GZ 2103.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Charles A. Nicolette	Assignee:	Genzyme Corp.
Filing Date:	August 3, 2001	Examiner:	Not Yet Assigned
Serial No.:	09/922,405	Group Art Unit:	1642
Title:	THERAPEUTIC ANTI-MELANOMA COMPOUNDS		

RESPONSE TO NOTICE TO COMPLY

U.S. Patent & Trademark Office
Box Sequence
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

This Response is submitted in reply to the Notice to Comply with Sequence Requirements issued by the U.S. Patent and Trademark Office on March 18, 2002, in connection with the above-identified application. A response to this Notice is due two months from the date of issuance, i.e., on or before May 18, 2002. Accordingly, this Response is timely filed.

The March 18, 2002 Notice, copy attached, indicated that the diskette filed in reply to the original Notice to Comply was unreadable and requested Applicant to submit a new diskette. Enclosed herewith is a replacement diskette having recorded thereon the information submitted with the paper copy, also enclosed herewith. The undersigned hereby states that the copy of the computer readable form, submitted in accordance with 37 C.F.R. § 1.825(b), is the same as the paper copy.

In the unlikely event that the transmittal letter is separated from this document and/or the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this

document to **Deposit Account No. 50-1189**, billing reference number **19442-7231**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Date: April 2, 2002


By: _____



Antoinette F. Konski

Reg. No. 34,202

McCutchen, Doyle, Brown & Enersen
Three Embarcadero Center, Suite 1800
San Francisco, CA 94111
Telephone: (650) 849-4950
Facsimile: (650) 849-4800



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/922,405	08/03/2001	Charles A. Nicolette	GZ-210300

CONFIRMATION NO. 7264

FORMALITIES LETTER



OC00000007662410

Antoinette F. Konski
McCutchen, Doyle, Brown & Enersen, LLP
18th Floor
Three Embarcadero Center
San Francisco, CA 94111

Date Mailed: 03/18/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE